

	BNT162b2 (n/N)	Placebo (n/N)	VE (%)	95% CI	mRNA-1273 (n/N)	Placebo (n/N)	VE (%)	95% CI	AZD1222 (n/N)
COVID-19 (without previous infection)									
all	8/17.411	162/17.511	95	90,0-97,9	11/14.134	185/14.073	94.1	89,3-96,8	74/7201 Interval 9-11 wks: 11/905
16-55/18-64 yrs	5/9.897	114/9.955	95.6	89,4-98,6	7/10.551	156/10.521	95.6	90,6-97,9	14/1.879 Interval>8 wks: 8/1407
>55/>65 yrs	3/7.500	48/7.543	93.7	80,6-98,8	4/3.583	29/3.552	86.4	61,4-95,2	1/341
≥65 yrs	1/3.848	19/3.880	94.7	66,7-99,9					
≥75 yrs	0/774	5/785	100	-13, -100	0/630	7/688	100	k.A.	
18-64 yrs without co- morbidities					5/8.396	121/8.403	95.9	90,0-98,3	
18-64 yrs with co- morbidities					2/2.155	35/2.118	94.4	76,9-98,7	
COVID-19 (with/without previous infection)									
all	9/18.559	169/18.708	94.6	89,9-97,3					
severe COVID-19									
all	1/21.314	4/21.259	75	-152,6-99,5	0/14.134	30/14.073	100	not calculated	0/12.021
Hospitalization due to COVID-19									
all									0/12.021
Death due to COVID-19									
all					0/14.134	1/14.073	100	k.A.	
COVID-19: after dose 1, before dose 2									
all	39/21.314	82/21.258	52.4	29,5-68,4	7/996	39/1079	80.2	55,2-92,5	
COVID-19: 14/15 days after dose 1, before dose 2									
all	2/21.669	27/21.686	92.6	68,9-98,2	2/14.550	35/14.598	94	76,0-99,0	
asymptomatic infection									
all									22/2.168 SDSD: 41/2.692

